Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (53,225,000)	$ (53,683,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	4,950,000	4,771,000
Depreciation	104,000	1,000
Acquisition of in-process research and development	0	13,117,000
Changes in the fair value of the warrant liability	0	29,817,000
Unrealized currency translation	148,000	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(517,000)	(38,000)
Deferred tax assets	208,000	0
Other assets	(2,098,000)	(100,000)
Accounts payable	(1,975,000)	370,000
Income tax payable	561,000	1,000
Accrued expenses	2,569,000	1,043,000
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc.	(2,299,000)	4,014,000
Deferred rent	213,000	0
Net cash used in operating activities	(51,361,000)	(687,000)
Cash flows from investing activities:
Purchases of furniture and equipment	(157,000)	0
Net cash used in investing activities	(157,000)	0
Cash flows from financing activities:
Cash capital contribution from Roivant Sciences Ltd.	0	831,000
Stock option exercises	12,000	0
Deferred initial public offering costs	0	(71,000)
Net cash provided by financing activities	12,000	760,000
Net change in cash	(51,506,000)	73,000
Cash—beginning of period	180,838,000	0
Cash—end of period	129,332,000	73,000
Non-cash investing and financing activities:
Deferred initial public offering costs, unpaid	0	1,603,000
Acquisition of in-process research and development	$ 0	$ 13,117,000